Takayama Koichi

24PUBLICATIONS
91CO-AUTHORS
ChemotherapyMedical infection agents (incl. prions)Predictive and prognostic markersMolecular targetsComputational neuroscience (incl. mathematical neuroscience and theoretical neuroscience)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (24)

|Jul 07, 2026
A Prospective Observational Study of Anamorelin During Chemoimmunotherapy in Non-Small Cell Lung Cancer With Cachexia (SPIRAL-ANA).

|Mar 24, 2026
Non-viable Aspergillus fumigatus promotes chronic inflammation and angiogenesis in a murine fungus ball model.

Ryosuke Hamashima, Masato Tashiro, Yuichiro Nakano

|Jul 10, 2025
Chemoimmunotherapy Outcomes and Prognostic Factors in Patients with Advanced, Low PD-L1-Expressing Non-Small Cell Lung Cancer.

Tae Hata, Tadaaki Yamada, Yasuhiro Goto

|May 19, 2025
Impact of immune-related adverse events on clinical outcomes in patients with advanced non-small cell lung cancer with low PD-L1 expression, focusing on pneumonitis: a multicenter retrospective study in Japan.

Shiho Goda, Tadaaki Yamada, Kenji Morimoto

|Nov 04, 2024
YAP Regulates HER3 Signaling-Driven Adaptive Resistance to RET Inhibitors in RET-Aberrant Cancers.

Yuki Katayama, Tadaaki Yamada, Keiko Tanimura

|Sep 14, 2024
The Significance of Longitudinal Psoas Muscle Loss in Predicting the Maintenance Efficacy of Durvalumab Treatment Following Concurrent Chemoradiotherapy in Patients with Non-Small Cell Lung Cancer: A Retrospective Study.

Haruka Kuno, Naoya Nishioka, Tadaaki Yamada

Pageof 4

Frequent Collaborators

15 joint publications

Tadaaki Yamada

9 joint publications

Akihiro Yoshimura

9 joint publications

Takayuki Takeda

7 joint publications

Uchino Junji